Empagliflozin’s Cardiorenal Benefits Appear to Persist 0 17.12.2024 03:00 Jamanetwork.com A follow-up of a randomized clinical trial found that positive effects of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, were seen up to a year after patients with chronic kidney disease stopped treatment. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
